Related Experiment Video
Updated: Mar 10, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
GPNMB ameliorates mutant TDP-43-induced motor neuron cell death
Yuki Nagahara1, Masamitsu Shimazawa1, Kazuki Ohuchi1
1Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Abstract:
Glycoprotein nonmetastatic melanoma protein B (GPNMB) aggregates are observed in the spinal cord of amyotrophic lateral sclerosis (ALS) patients, but the detailed localization is still unclear. Mutations of transactive response DNA binding protein 43kDa (TDP-43) are associated with neurodegenerative diseases including ALS. In this study, we evaluated the localization of GPNMB aggregates in the spinal cord of ALS patients and the effect of GPNMB against mutant TDP-43 induced motor neuron cell death. GPNMB aggregates were not localized in the glial fibrillary acidic protein (GFAP)-positive astrocyte and ionized calcium binding adaptor molecule-1 (Iba1)-positive microglia. GPNMB aggregates were localized in the microtubule-associated protein 2 (MAP-2)-positive neuron and neurofilament H non-phosphorylated (SMI-32)-positive neuron, and these were co-localized with TDP-43 aggregates in the spinal cord of ALS patients. Mock or TDP-43 (WT, M337V, and A315T) plasmids were transfected into mouse motor neuron cells (NSC34). The expression level of GPNMB was increased by transfection of mutant TDP-43 plasmids. Recombinant GPNMB ameliorated motor neuron cell death induced by transfection of mutant TDP-43 plasmids and serum-free stress. Furthermore, the expression of phosphorylated ERK1/2 and phosphorylated Akt were decreased by this stress, and these expressions were increased by recombinant GPNMB. These results indicate that GPNMB has protective effects against mutant TDP-43 stress via activating the ERK1/2 and Akt pathways, and GPNMB may be a therapeutic target for TDP-43 proteinopathy in familial and sporadic ALS. © 2016 Wiley Periodicals, Inc.
Insights
Glycoprotein nonmetastatic melanoma protein B (GPNMB) aggregates are found in neurons of ALS patients, co-localized with TDP-43 aggregates. GPNMB protects motor neurons from mutant TDP-43 toxicity by activating ERK1/2 and Akt pathways.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Glycoprotein nonmetastatic melanoma protein B (GPNMB) aggregates are present in the spinal cord of amyotrophic lateral sclerosis (ALS) patients.
- The precise localization of GPNMB aggregates and their role in ALS pathogenesis, particularly in relation to transactive response DNA binding protein 43kDa (TDP-43) mutations, remain unclear.
Purpose of the Study:
- To investigate the localization of GPNMB aggregates in the spinal cord of ALS patients.
- To determine the effect of GPNMB on mutant TDP-43-induced motor neuron cell death.
Main Methods:
- Immunohistochemical analysis of GPNMB, TDP-43, GFAP, Iba1, MAP-2, and SMI-32 in spinal cord tissues from ALS patients.
- Transfection of mouse motor neuron cells (NSC34) with wild-type and mutant TDP-43 plasmids.
- Assessment of GPNMB expression, cell viability, and activation of ERK1/2 and Akt pathways.
Main Results:
- GPNMB aggregates were localized in neurons (MAP-2 and SMI-32 positive) and co-localized with TDP-43 aggregates in ALS spinal cords, but not in astrocytes or microglia.
- Expression of GPNMB increased upon transfection with mutant TDP-43 plasmids.
- Recombinant GPNMB protected motor neurons from mutant TDP-43-induced cell death and serum-free stress, and restored ERK1/2 and Akt pathway activation.
Conclusions:
- GPNMB exhibits protective effects against mutant TDP-43-induced neurotoxicity by activating the ERK1/2 and Akt signaling pathways.
- GPNMB represents a potential therapeutic target for TDP-43 proteinopathies, including familial and sporadic ALS.

